메뉴 보기
link 세부 정보
정보 바로가기 : With Korea nod for Prolia biosimilar, Samsung Bioepis moves in on Celltri...
With Korea nod for Prolia biosimilar, Samsung Bioepis moves in on Celltri...[카테고리 설정이 아직되어 있지 않습니다.]
density (BMD)—showing comparable outcomes between the two groups. At the lumbar spine, Obodence increased BMD by 5.6 percent, compared to 5.3 percent for Prolia. At the hip, the gains were 3.5...
